Headquarters: Redwood City, California, United States
52 week low:
52 week high:
Next ER:November 8, 2021 After Market Closes
Top Stories (CHRS)
Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus? biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California?s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.
Talk about Coherus Biosciences Inc below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.